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Summary--l,25-Dihydroxyvitamin D3, [1,25(OH) 2D3], the biologically most active metabolite 
of vitamin D3, is involved in the regulation of calcium homeostasis and bone metabolism. 
Recently, receptors for 1,25(OH)2D3 have also been shown in cells and tissues not directly 
related to calcium homeostasis. Experimental data obtained with ieukaemic and cancer cell 
lines, both in vitro and in vivo, showed the effects of 1,25(OH)2D 3 on cell differentiation a d 
proliferation. However, high doses of the sterol have to be used to observe these effects. 
Additional studies are needed to establish whether 1,25(OH)2D3 or suitable analogues have a 
therapeutic potential in malignant diseases without unacceptable toxicity like the development 
of hypercalcemia. 
INTRODUCTION 
Studies of the function and endocrinology of 
vitamin D over the last 80 years have elucidated 
its role as an important regulator of calcium and 
phosphate homeostasis. However, current evi- 
dence also suggest hat the vitamin D endocrine 
system is involved in the modulation of a number 
of fundamental cellular processes not directly 
related to calcium homeostasis (for reviews see 
Refs [1-3]). In this brief review the effects of 
the most active metabolite of vitamin D, 
1,25-dihydroxyvitamin D 3 [1,25(OH)2 D3 ] on cell 
differentiation and proliferation will be discussed. 
VITAMIN D: 
METABOLISM AND MODE OF ACTION 
The term vitamin D is a misnomer: cholecal- 
ciferol is not a vitamin in the generally accepted 
sense of an essential dietary requirement. It is 
synthesized photochemically in the skin and 
adequate amounts are produced with sufficient 
exposure to sunlight. It is also absorbed from 
the diet. 1,25(OH)2D3, is formed by two subse- 
quent hydroxylations in the liver (25-hydroxyl- 
ase) and the kidney (10~-hydroxylase) and exerts its 
effect via a specific receptor [3]. The 1,25(OH)2D 3 
receptor belongs to the superfamily of steroid 
hormone receptors [4]. 1,25(OH)2D 3 receptors 
are not confined to the classical target tissues, 
which play an important role in calcium borneo- 
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stasis but these receptors are also found in a 
wide variety of so-called non-classical target 
tissues (Table l)[3]. In several of these target 
tissues 1,25(OH)2D 3 undergoes an extensive 
side-chain oxidation at the C24 position [2]. 
This catabolism of the hormone is induced 
by 1,25(OH)2D3 itself and may have a dual 
effect: (1) directly by regulation of the cellular 
concentration of the hormone; and (2) indirectly 
by its ability to modulate the ligand-dependent 
up-regulation of the 1,25(OH)2D3 receptor [5]. 
Table 1. Tissue distribution of the 
1,25(OH)2 D3 receptor 
Normal mammalian tissues or cell types 
Intestine 
Kidney 
Parathyroid glands 
Bone 
Skin (epidermal nd fibroblasts) 
Skeletal muscle (myoblast) 
Cardiac muscle 
Mammary tissue 
Testes 
Ovary 
Uterus 
Placenta 
Pancreas 
Colon 
Parotid gland 
Thymus 
Circulating lymphocytes (activated) 
Circulating monocytes 
Malignant issues or cancer-cell lines 
Osteosarcoma 
Melanoma 
Breast carcinoma 
Colon carcinoma 
Medullary thyroid carcinoma 
Myeloid and lymphocyte l ukaemia 
Pancreatic adenocarcinoma 
Transitional bladder carcinoma 
Cervical carcinoma 
Fibrosarcoma 
According to Reichel et al. [3]. 
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EFFECTS ON CELL PROLIFERATION 
AND DIFFERENTIATION 
The identification of 1,25(OH)2D3 receptors 
in tissues not directly related to mineral homeo- 
stasis raises the question whether 1,25(OH)2D3 
has other functions. In 1981 Abe et a/.[6] 
demonstrated for the first time that 1,25(OH)~ D3 
induces differentiation of mouse myeloid leu- 
kaemia cells into monocytes-macrophages. Thi  
original observation was extended to other 
tissues and cells, especially haematopoietic 
and cancer cell lines [7, 8]. All these studies 
indicated that 1,25(OH)2D3 may play a role 
in the regulation of cell differentiation and/or 
proliferation. 
Haematopoiet ic cells 
Leukaemic cell lines are frequently used 
models to study the effects of 1,25(OH)2D3 on 
haematopoietic differentiation. The overall effect 
of treatment of these cells with 1,25(OH)2D3 is a 
reduced proliferation and a preferential differen- 
tiation along the monocyte-macrophage path- 
way [8]. It is of interest hat these alterations 
are preceded by modulations in the expression 
of oncogenes. Reitsma et al. [9] showed that 
1,25(OH)2D 3 reduces c-myc mRNA levels in 
HL-60 cells within 4 h of exposure to the sterol 
and that this change precedes the onset of other 
measured phenotypic hanges by at least 8 h. 
Other investigators showed that this inhibition 
of c-myc gene expression is accompanied by a 
decreased expression of the c-myb gene. At the 
same time a transient activation of the c-fos and 
a sustained expression of c-fms was observed 
[10]. Finally, recent evidence suggest hat the 
action of 1,25(OH):D3 to induce H1-60 cell 
differentiation and modulate c-myc transcription 
requires protein kinase C activity [11]. Whether 
the changes in expression of oncogenes are 
directly related to differentiation remains to be 
elucidated. 
1,25(OH)2D3 not only induces in vitro 
differentiation of leukaemic ell lines but also 
of normal bone marrow progenitor cells into 
monocyte-macrophages [12, 13]. Furthermore, 
1,25(OH)2D 3seems to be involved in the activa- 
tion and also the fusion of macrophages to multi- 
nucleated giant cells [8]. With respect o mineral 
homeostasis t is important o emphasize that 
1,25(OH)2D 3 also seems to play a role in the 
osteoclastogenesis. Immature bone marrow 
cells of the monocyte-macrophage lin age are 
thought o be precursors of the bone-resorbing 
cells, the osteoclasts. In this way, 1,25(OH)2 D3 
may regulate skeletal homeostasis, at least in 
part, by modulating differentiation, fusion and 
activation of haematopoetic progenitors [8]. 
The marked effects of 1,25(OH)2 D3 on growth 
and differentiation of leukaemic ells in vitro led 
Homna et al. [14] to examine whether in vivo 
administration of 1,25(OH)2D 3 to nude mice 
inocculated with murine myeloid leukaemia 
(M1) cells would decrease leukaemogenicity. 
Treatment with 1,25(OH)2D3 or lct(OH)D 3 
[rapidly converted in the liver to 1,25(OH)2D3] 
considerably prolongs the survival of the mice 
compared to vehicle-treated animals. 
Studies in humans are scanty. Preliminary data 
obtained by Cunningham et al. [15] suggested 
antitumour activity in patients with low grade 
non-Hodgkin lymphomas. In contrast, reatment 
of patients with myelodysplastic syndrome with 
2#g 1,25(OH)2D3 daily did not result in an 
apparent improvement [16]. One of the major 
problems for further clinical studies with 
1,25(OH)2D3 is hypercalcemia, because supra- 
physiological doses are needed. 
Cancer cells 
As shown in Table 1, 1,25(OH)2D 3receptors 
are present in a wide variety of cancer cell 
lines and tissues. The initial observation that 
1,25(OH)2D3 inhibits cell growth in cancer cells 
was made in melanoma cells[17], and subse- 
quently similar effects were observed in a still 
growing number of other cancer cell lines [7]. 
In our laboratory we have studied the effect on 
cell growth in the rat osteosarcoma cell UMR- 
106. As shown in Fig. 1, 1,25(OH)2D 3 elicits 
a time-dependent decrease in the incorporation 
of [3H]thymidine. However, relatively high 
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Fig. 1. UMR-106 cells were seeded at a density of 
50,000cells/cm 2 and cultured in ~tMEM with 10% FCS. 
After 24 h the medium was changed to ctMEM with 2% 
charcoal-treated FCS with ([]) or without 10 -SM 
1,25(OH)2D 3 (r-l). After the times indicated [3H]thymidine 
incorporation was measured during the final hour of culture, 
as described by van der Plas et aL [30]. 
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Fig. 2(a,b). MCF-7 cells were seeded at a density of 50,000 cells/cm 2 and cultured in RPMI-1640 with 10% 
FCS. After 24 h the medium was changed to RPMI-1640 with 4.5% FCS (I-q) or 10% FCS (1~). At the 
same time vehicle or various concentrations of 1,25(OH)2D 3 were added. Dual-parameter flow propidium 
iodide uptake in DNA was used to study the effects of 1,25(OH)2D3 on cell-cycle kinetics at 24 h of 
incubation [31]. 
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concentrations of 1,25(OH)2D3 (> 10 -9 M) are 
needed to obtain inhibition of cell growth. Also, 
in other studies comparable concentrations of 
1,25(OH)2D3 had to be used to inhibit cell 
replication in vitro [7, 17, 18]. In some cases, 
inhibition of cell growth is coupled to morpho- 
logical changes [18-20]. 
To gain more insight into the effects of 
1,25(OH)2D3 on proliferation we studied its 
effect on cell cycle kinetics. For this purpose 
we used MCF-7 cells, a 1,25(OH)2D3 receptor 
positive human breast cancer cell line. As shown 
in Fig. 2(a), we observed after 24 h a dose- 
dependent decrease in the number of cells in 
the S-phase and a concomitant increase in cell 
number in the G0/Gt phase of the cell cycle [Fig. 
2(b)]. During these relatively short incubations 
no change in the number of cells in the G2 phase 
was observed (data not shown). Taken together 
these results indicate that treatment with 
1,25(OH)2D 3results in an accumulation fcells 
in the G0/G1 phase of the cell cycle. Comparable 
results were obtained using the rat osteosarcoma 
cell line UMR-106 (data not shown). Recently, 
Eisman et al. [21] also showed that in T47D 
breast carcinoma cells 1,25(OH)2D3 inhibited 
progression through the G0/G~ phase. However, 
in contrast to our observations, they also found 
a transition delay in G2 + M. This may be due 
to differences in experimental conditions, e.g. a 
longer incubation time (6 days). 
It is important to emphasize that for growth 
reduction by 1,25(OH)2D 3 supraphysiological 
concentrations (> 10 -9 M) are needed. Finally, 
from our own data [Fig. 2(a,b)] the anti- 
proliferative ffect of 1,25(OH)2D 3 in MCF-7 
cells seems more potent in rapidly dividing cells 
cultured in 10% FCS, compared to cells cultured 
in 4.5% FCS which are growing more slowly 
[Fig. 2(a,b)]. Whether this indicates an inter- 
action of 1,25(OH)2D 3 with the response to 
growth factors present in the medium remains 
to be elucidated. However, the recent finding of 
a down-regulation by 1,25(OH)2 D3 of epidermal 
growth factor receptors in T47D cells [22] at 
least suggests that such a mechanism could play 
a role. 
The antiproliferative effect of 1,25(OH)2D 3 
has been confirmed in vivo. In high doses the 
sterol inhibits growth of human malignant mela- 
noma and colonic cancer xenografts in immune 
suppressed mice [23] and of nitrosomethylurea- 
induced mammary tumours in rats [24], while 
administration of I~(OH)D 3 reduced the 
number of lung metastases after implantation of
Lewis lung carcinoma cells into mice [25]. The 
fact that 1,25(OH)2D 3 stimulates fibronectin 
synthesis n several human cancer cell lines may 
be related to the possible antimetastatic effect of 
the hormone [26]. 
CONCLUSION 
From the data currently available it seems 
clear that 1,25(OH)2D3 has a regulatory effect 
on cell growth and proliferation. However, high 
doses of the sterol are needed. Therefore, it 
remains to be established whether 1,25(OH)2D 3 
can produce long-term antitumour effects with- 
out unacceptable toxicity, like the development 
of hypercalcemia. In this light, the recent devel- 
opment of new vitamin D analogues which have 
potent effects on cell proliferation and differ- 
entiation in vitro without inducing severe hyper- 
calcemia is of interest [27-29]. 
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